فهرست مطالب گلرخ شرافتی

Intrauterine adhesion is a condition that can lead to infertility, amenorrhea, repeated abortion in the patient, and the treatment of these patients is usually associated with many challenges. The present study was performed with aim to compare the effect of two different doses of estrogen to prevent the recurrence of adhesions after hysteroscopic lysis in Asherman's syndrome.

This randomized controlled clinical trial study was performed on 30 patients with moderate and severe Asherman's syndrome in Imam Reza Hospital of Mashhad, 2017-2021. Patients underwent hysteroscopy to remove adhesions. For all patients, an intrauterine balloon was placed after the operation and then they were treated with estrogen for 30 days and medroxyprogesterone 10 mg daily for the last 10 days. Patients were randomly assigned to two groups of estrogen 2.5 mg and 5 mg daily. After the end of the treatment period, with hysteroscopy again, the state of the uterine cavity was checked and the response to the treatment was compared in terms of the return of adhesions and its intensity in the two groups. Data were analyzed using SPSS software (version 26) and Shapiro-Wilk and Mann-Whitney U statistical tests. P<0.05 was considered statistically significant.

The most common cause of Asherman in the 2.5 mg group was curettage (60%) and in the 5 mg group, other surgeries (60%). The two groups had no statistically significant difference in terms of confounding variables including age, cause of Asherman's disease and severity of adhesions (p=0.714). In examining the response to treatment, there was no statistically significant difference between the two groups in terms of adhesion severity in repeated hysteroscopy (p=0.858) and response to treatment (p=0.714).

For the prevention of recurrence of intrauterine adhesions (Asherman's syndrome) after hysteroscopic lysis of adhesions, the dose of 2.5 mg of Conjugated estrogen was as effective as the dose of 5 mg of estrogen.

Standard treatment of Gestational Trophoblastic Disease (GTD) is chemotherapy. Single-agent chemotherapy regime including Methotrexate (MTX) or Actinomycin. Single-agent is widely used in treatment of persistent trophoblastic disease. We reported an uncommon toxicity of low-dose single-agent methotrexate in a patient.

A 20-year-old woman, primary gravid after two months missed period and spotting with diagnosis of incomplete abortion with uterine size equivalent of ten weeks pregnancy (8-10 cm) underwent evacuation curettage. In serial follow-up, based on rise of beta-hCG titer and absence of metastatic disease, it was categorized as low-risk persistent trophoblastic disease. She was referred to gynecology oncology center of Ghaem Hospital, Mashhad University of Medical Sciences in May 2014. Because of rise of beta-hCG titer, after complete metastatic work-up and lack of disease in other sites, persistent disease was diagnosed and candidate for chemotherapy (single agent low-dose). The patient received first course of therapy with MTX (50 mg/m², intra muscular). Unfortunately, after two days of treatment she developed uncommon severe toxicity, fever, severe nausea and vomiting, tachycardia, and generalized weakness. Also, we found hematologic abnormality (WBC: -14000-15000 µI, platelet- 540 µI and sever neutropenia), and abnormal rising in liver function test (SGOT, SGPT) (three to four times) and renal function test (BUN and Creatinine) (two times). In addition, she had disseminated erosive lesion in all of body especially in face. Due to the fatal side effects of chemotherapy, she was admitted to intensive care unit (ICU). Fortunately, after two to three weeks, she was improved by conservative management. After few weeks beta-hCG titer was in normal limit. However she had normal serial beta-hCG in one year of follow-up.

It is important to emphasis unpredictable side effects of chemotherapy with low-dose methotrexate.

Cervix is a rare and dangerous site for ectopic pregnancy. When the placenta is implanted lower than internal cervical os, it is called “cervical pregnancy”. Known risk factors for cervical pregnancy are previous cesarean section, cigarette smoking, premature transfer of fertilized ovum before having suitable endometrium and pelvic inflammatory disease. In the past, hysterectomy was the usual treatment. Nowadays, with the newer diagnostic and therapeutic managements, cases of cervical pregnancy treated by fertility sparing methods have been reported. Conservative treatments include using methotrexate and KCl, hyperosmolar glucose, and prostaglandins. Also, surgical methods with fertility sparing have been reported. The purpose of this study is introducing two cases of cervical pregnancies treated by fertility sparing. The first patient had six weeks pregnancy with live fetus and detectable fetal heart beat. There was six weeks menstrual retard and βhCG titer was 10.000 UI/ml. Two doses of methotrexate were prescribed and pregnancy terminated successfully. The other patient had eight weeks pregnancy with fetal heart beat. There was eight weeks retardation and βhCG titer was 70379 UI/ml with no gestational sac in sonography in both patients. After prescribing two doses of methotrexate and doing curettage three days after the last dose of methotrexate, pregnancy terminated. The known risk factors for our patients were history of endometrial curettage in one and history of cesarean section in both of them. Conservative method may be considered for the treatment of cervical pregnancy in patients who desire to preserve their fertility. The treatment is associated with high success rates. Methotrexate (MTX) is the most common medicine for resolving ectopic cervical pregnancy, other medications such as KCl, hyperosmolar glucose, RU486 and prostaglandins have also been used with different success rate. Methotrexate may be administered systemic (intramuscular or intravenous) or local (intra-amniotic transfusion or intrauterine).